Navigation Links
Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
Date:10/27/2008

SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc., (Nasdaq: NLTX), announced today that Peter Strumph, Chief Executive Officer, will present at the 7th Annual BIO Investor Forum on Thursday, October 30th, at 9:00 a.m. PT at The Palace Hotel in San Francisco.

Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including interim data from Nile's Phase 2a study for its lead compound, CD-NP, a novel chimeric peptide for the treatment of heart failure.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section of Nile's website at http://www.nilethera.com. The webcast will be archived for 90 days.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nektar Therapeutics to Webcast R&D Day on November 12th
2. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
3. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
4. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
5. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
6. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
7. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
10. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the ... and a beautiful technology experience. All three tenets were on display at the 2nd ... leaders from over 40 sponsor, CRO and site organizations to discuss innovation and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center ... 3rd, 2016. The event, which is held on the United Nations International Day of ... Disabilities back into the workplace. Suitable Technologies is partnering with NTI to showcase how ...
(Date:12/2/2016)... Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease ... Kenya,s Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy ...
(Date:11/30/2016)... 2016 The global Pyrogen Testing ... a dominant share in the overall market. The leading ... and Merck KGaA, held a lion,s share of 51% ... observes that these companies are expected to retain their ... are do not require rabbit pyrogen testing along with ...
Breaking Biology Technology:
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
Breaking Biology News(10 mins):